Bupivacaine Liposomal Injection (Exparel) for Postsurgical Analgesia in Patient Undergoing Laparoscopic Bariatric Surgery
Bupivacaine Liposomal Injection (Exparel) for Postsurgical Analgesia in Patients Undergoing Laparoscopic Bariatric Surgery: A Randomized, Double-Blind, Controlled Trial
Sponsor: The Cleveland Clinic
This PHASE4 trial investigates Pain, Postoperative and is currently completed. The Cleveland Clinic leads this study, which shows 10 recorded versions since 2016 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Dec 2021 — Jul 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE4
-
Apr 2020 — Jan 2021 [monthly]
Completed PHASE4
Status: Unknown Status → Completed
▶ Show 5 earlier versions
-
Dec 2019 — Apr 2020 [monthly]
Unknown Status PHASE4
Status: Recruiting → Unknown Status
-
Jun 2018 — Dec 2019 [monthly]
Recruiting PHASE4
-
Dec 2017 — Jun 2018 [monthly]
Recruiting PHASE4
-
Feb 2017 — Dec 2017 [monthly]
Recruiting PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE4
First recorded
Nov 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- The Cleveland Clinic
For direct contact, visit the study record on ClinicalTrials.gov .